{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:33:38Z","timestamp":1790660018754,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jtct.2023.11.008","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T02:57:22Z","timestamp":1699585042000},"page":"131-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan E.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4509-2232","authenticated-orcid":false,"given":"Linda","family":"Ramsdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4528-6367","authenticated-orcid":false,"given":"Shakthi T.","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-7824","authenticated-orcid":false,"given":"Katie","family":"Gatwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jtct.2023.11.008_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2023.11.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2023.11.008_bib0003","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jtct.2023.07.002","article-title":"Updated Indications for immune effector cell therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2023.11.008_bib0004","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2023.11.008_bib0005","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2023.11.008_bib0006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2023.11.008_bib0007","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASBMT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2023.11.008_bib0008","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1189\/jlb.5BT1115-524R","article-title":"At the bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies","volume":"100","author":"Oluwole","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.jtct.2023.11.008_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2023.11.008_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2023.11.008_bib0011","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jtct.2023.11.008_bib0012","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jtct.2023.11.008_bib0013","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2023.11.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7554","article-title":"Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma","volume":"39","author":"Bansal","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2023.11.008_bib0015","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1016\/j.clml.2022.04.012","article-title":"Outcomes of tisagenlecleucel in lymphoma patients with predominant management in an ambulatory setting","volume":"22","author":"Nasta","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.jtct.2023.11.008_bib0016","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jtct.2022.06.021","article-title":"Real-world experience and optimization of outpatient chimeric antigen receptor T cell therapy","volume":"28","author":"McGann","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2023.11.008_bib0017","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/bjh.18339","article-title":"Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: the Vanderbilt experience","volume":"198","author":"Dholaria","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2023.11.008_bib0018","doi-asserted-by":"crossref","first-page":"449.e1","DOI":"10.1016\/j.jtct.2023.04.019","article-title":"Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma","volume":"29","author":"Ahmed","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2023.11.008_bib0019","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.19090","article-title":"Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages","volume":"203","author":"Ly","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2023.11.008_bib0020","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center","volume":"57","author":"Borogovac","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2023.11.008_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2023.11.008_bib0022","article-title":"Successful development of an outpatient chimeric antigen receptor (CAR) T cell therapy program","volume":"138","author":"Borogovac","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2023.11.008_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2023.11.008_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2023.11.008_bib0025","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1017\/S1478951514000947","article-title":"Delirium screening anchored in child development: The Cornell Assessment for Pediatric Delirium","volume":"13","author":"Silver","year":"2015","journal-title":"Palliat Support Care"},{"issue":"3","key":"10.1016\/j.jtct.2023.11.008_bib0026","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","article-title":"Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU","volume":"42","author":"Traube","year":"2014","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.jtct.2023.11.008_bib0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2023.11.008_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.841117","article-title":"Cytokine release syndrome and associated acute toxicities in pediatric patients undergoing immune effector cell therapy or hematopoietic cell transplantation","volume":"12","author":"Baumeister","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2023.11.008_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2023.11.008_bib0030","unstructured":"Helping families feel at home\u2014 even when they can't be. Available from: https:\/\/rmhc.org. Accessed 9\/1\/2023."},{"issue":"3","key":"10.1016\/j.jtct.2023.11.008_bib0031","first-page":"1167","article-title":"Patient housing barriers to hematopoietic cell transplantation: results from a mixed-methods study of transplant center social workers","volume":"24","author":"Preussler","year":"2016","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2023.11.008_bib0032","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12913-017-2529-0","article-title":"The influence of family accommodation on pediatric hospital experience in Canada","volume":"17","author":"Franck","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.jtct.2023.11.008_bib0033","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1037\/a0033556","article-title":"Accommodating families during a child's hospital stay: implications for family experience and perceptions of outcomes","volume":"31","author":"Franck","year":"2013","journal-title":"Fam Syst Health"},{"issue":"8","key":"10.1016\/j.jtct.2023.11.008_bib0034","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2023.11.008_bib0035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtct.2023.11.008_bib0036","doi-asserted-by":"crossref","unstructured":"Gatwood KS, Dholaria BR, Lucena M, Baer B, Savani BN, Oluwole OO. Chimeric antigen receptor T-cell therapy: challenges and framework of outpatient administration. EJHaem. 2022;3(Suppl 1):54-60.","DOI":"10.1002\/jha2.333"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:11:25Z","timestamp":1763003485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723016755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666636723016755"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.11.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}